5 Big Winners and Losers From Earnings Season: Pfizer Inc. (PFE), Merck & Co., Inc. (MRK), Eli Lilly & Co. (LLY)

Page 1 of 2

Earnings season is a wrap for many of the brightest stars of the health care sector: Big pharma’s big disappointments and successes are in the books, and investors are looking ahead to the future. Patent expirations have been taking their toll on sales of some of the industry’s biggest blockbuster drugs lately, putting pharmaceutical firms on the defensive as they try to boost pipeline stockpiles and stave off revenue losses. With that in mind, how did five of big pharma’s biggest names grade out this earnings season?

Pfizer Inc. (NYSE:PFE)Earnings season’s big winner: Pfizer Inc. (NYSE:PFE)
After a great 2012, Pfizer Inc. (NYSE:PFE) has opened up 2013 with a bang. The company’s $11.85 billion sale of its nutrition business to Nestle last year has rewarded shareholders, as Pfizer reported fourth-quarter profit that more than quadrupled last year’s total. Earnings per share of $0.85 — drastically up from $0.19 a year ago — made investors happy, although adjusted EPS that removed one-time items fell slightly by $0.02 to $0.47; still, that beat analyst profit projections of $0.44 per share for the quarter.

All the talk now surrounds Pfizer’s recent debut of former animal health business Zoetis Inc (NYSE:ZTS) as a publicly traded company following its recent IPO, but Pfizer’s still dealing with issues of its own. The company faces plenty of generic competition for drugs — particularly blockbuster Lipitor, which lost patent protection last year — in what’s become an industrywide trend. However, with a massive pipeline of 87 drugs to bolster the future, Pfizer could make up for falling revenues, which declined 7% this past quarter, by scoring a few timely FDA approvals.

Ultimately, Pfizer could be one of the better-positioned companies for the future after it scored one of the industry’s best earnings reports, particularly as its rivals have struggled as of late.

Future imperfect: Merck & Co., Inc. (NYSE:MRK)
Fellow Dow Jones member Merck & Co., Inc. (NYSE:MRK) hasn’t had so much to cheer about recently despite a strong 2012. The company actually reported an earnings beat despite the negativity that’s surrounded it in past days; Merck’s earnings per share came in at $0.83, $0.02 higher than analysts projected, while revenue of $11.7 billion also beat expectations. Both fell from a year ago — and it’s the future, not the present, that has investors so concerned.

The company warned investors that generic competition will cut into 2013 profits as Merck continues to feel the pain from patent expirations, particularly on blockbuster drug Singulair. The company’s still got a handle on strong products for the future, such as blockbuster diabetes therapies Januvia and Janumet and fast-growing cervical cancer vaccine Gardasil — each of which posted strong  double-digit sales growth this past quarter — but the caution wasn’t what shareholders wanted to hear.

Singulair sales flopped by 67% this past quarter — and by 30% for 2012 as a whole — showing just how bad the patent cliff is hurting Merck’s sales. With the company delaying its filing for FDA approval on promising osteoporosis drug odanacatib until 2014, the year ahead for Merck has become considerably tougher.

The pain of patent losses: Eli Lilly & Co. (NYSE:LLY) and Bristol Myers Squibb Co. (NYSE:BMY)
Generic sales have cut a wide swath across big pharma with the patent cliff, and Eli Lilly & Co. (NYSE:LLY) and Bristol Myers Squibb Co. (NYSE:BMY) felt the pain this quarter. The former’s still feeling the pain from the 2011 patent expiration of once-blockbuster drug Zyprexa, as the drug’s sales fell 49% in the fourth quarter to under $400 million — after at one point selling more than $5 billion annually. Eli Lilly’s earnings per share fell by $0.03 year-over-year to $0.74 for the quarter, with revenue also falling around 1%. Still, the company’s numbers did manage to beat estimates. Furthermore, Eli Lilly’s pipeline holds several promising therapies in oncology and diabetes that could help the stock’s recent run-up should any of them score FDA approval and would ease the loss of patent protection on blockbuster depression drug Cymbalta this December.

Bristol-Myers managed to boost earnings per share by 12% in a delight for investors — a good thing, too, since the company’s revenue fell by an ugly 23%, with an ungodly 38% fall in U.S. sales for the quarter. Like Eli Lilly, patent losses took a bite out of the company: Sales of Avapro and Plavix, each which recently lost patent protection, especially hurt, with Plavix revenue falling a ridiculous 97% for the quarter.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

Top 6 Cities For The Ultra Rich to Live in Comfort

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!